| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Zejing Wang | Q125345672 |
| Rainer Storb | Q19546769 | ||
| P2093 | author name string | Stephen J Tapscott | |
| Jeffrey S Chamberlain | |||
| P2860 | cites work | Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 |
| Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products | Q45868913 | ||
| Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector | Q45872994 | ||
| Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation | Q45879591 | ||
| Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin | Q45881869 | ||
| Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy | Q45888356 | ||
| The muscular dystrophies | Q77731754 | ||
| Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression | Q80141652 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle | Q33713019 | ||
| Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery | Q33730464 | ||
| Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging | Q33731159 | ||
| Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure | Q33786029 | ||
| Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. | Q33931862 | ||
| Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. | Q34025098 | ||
| Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs | Q34080895 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. | Q34266296 | ||
| Systemic delivery of genes to striated muscles using adeno-associated viral vectors. | Q34347199 | ||
| Gene therapy for muscular dystrophy - a review of promising progress | Q35184730 | ||
| Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results | Q35496285 | ||
| Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model | Q35847459 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. | Q35889903 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. | Q36968852 | ||
| A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. | Q37245439 | ||
| AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells | Q37348251 | ||
| Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 | ||
| Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature | Q37460257 | ||
| Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle | Q39639059 | ||
| Dystrophin immunity in Duchenne's muscular dystrophy. | Q41590387 | ||
| Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins | Q43268180 | ||
| Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy | Q43801966 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy | Q45409051 | ||
| Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid | Q45414481 | ||
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 201 | |
| P577 | publication date | 2011-09-26 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials | |
| P478 | volume | 2 |
| Q59354485 | Q59354485 |
| Q34814931 | A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer |
| Q90732125 | AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice |
| Q59355420 | An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK. to Leg Skeletal Muscles in the Rhesus Macaque |
| Q36966955 | CpG-depleted adeno-associated virus vectors evade immune detection. |
| Q36270357 | Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9. |
| Q92547654 | Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity |
| Q39035949 | Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector |
| Q37686976 | Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model |
| Q36295934 | Gene Therapy for Duchenne muscular dystrophy |
| Q34566454 | Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors |
| Q42227245 | Gene therapy research at the frontiers of viral immunology. |
| Q38195598 | Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside |
| Q40928395 | Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways |
| Q94491267 | In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin |
| Q33736192 | Influence of immune responses in gene/stem cell therapies for muscular dystrophies |
| Q47345657 | Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies. |
| Q59358387 | Molecular Therapies for Muscular Dystrophies |
| Q41136552 | Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. |
| Q30655090 | Optogenetic control of contractile function in skeletal muscle |
| Q36582796 | Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector |
| Q38012709 | Phoenix rising: gene therapy makes a comeback |
| Q34497471 | Progress and prospects of gene therapy clinical trials for the muscular dystrophies. |
| Q26741409 | Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials |
| Q35750023 | Signs of progress in gene therapy for muscular dystrophy also warrant caution |
| Q36142496 | Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies |
| Q38257312 | The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense Oligonucleotides in mdx Mice |
| Q38539938 | The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer |
| Q33902499 | The potential of adeno-associated viral vectors for gene delivery to muscle tissue |
Search more.